EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 13-Jul-2025 06:11 ET (13-Jul-2025 10:11 GMT/UTC)

AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life. Acne-like skin rash is a common side effect from colorectal cancer treatment, often causing patients to postpone their treatments. LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself. Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo.

AI-driven biomarker model may improve detection of cancer cachexia

American Association for Cancer Research
Reports and Proceedings

An AI-driven biomarker model that analyzes routine imaging and clinical information may improve the detection of cancer cachexia, according to results presented by Sabeen Ahmed at AACR Annual Meeting 2025.

Off-the-shelf CAR natural killer cell therapy with logic gates elicits complete remissions in relapsed or refractory blood cancers

American Association for Cancer Research
Reports and Proceedings

SENTI-202, an off-the-shelf, logic-gated, CAR natural killer cell therapy drove complete remission of pretreated blood cancers in a first-in-human trial, according to results presented by Stephen Strickland Jr., MD, MSCI, at AACR Annual Meeting 2025.

Pretrained machine learning models may help accurately diagnose nonmelanoma skin cancer in resource-limited settings

American Association for Cancer Research
Reports and Proceedings

Pretrained machine learning models may help accurately diagnose nonmelanoma skin cancer in resource-limited settings, according to presenter Steven Song at AACR Annual Meeting 2025.

AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial

University of Texas M. D. Anderson Cancer Center
Reports and Proceedings

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations. In this combination trial patients were matched by genetic features, not tumor type – a tumor-agnostic, molecularly matched trial that included 30 different cancer types. Prior studies indicated potential for synergy between these two therapies, and this study verified this in multiple advanced solid tumors, especially in certain subsets of patients. Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies.

Moffitt study uncovers a way to boost treatment for aggressive melanoma

H. Lee Moffitt Cancer Center & Research Institute
Peer-Reviewed Publication

A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.

Journal: Cancer Research
Funder: NIH/National Institutes of Health
Meeting: AACR Annual Meeting 2025

Adding perioperative pembrolizumab to standard of care improves outcomes in patients with newly diagnosed head and neck cancer

American Association for Cancer Research
Reports and Proceedings

Supplementing standard therapy with perioperative PD-1 blockade benefitted patients with untreated, locally advanced head and neck cancer in a phase III clinical trial, according to results presented by Ravindra Uppaluri, MD, at the AACR Annual Meeting 2025.

Meeting: AACR Annual Meeting 2025

Immunotherapy improves survival of patients with locally advanced head and neck cancer

WashU Medicine
Reports and Proceedings

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.

Funder: Merck Sharp & Dohme LLC
Meeting: AACR Annual Meeting 2025

Oral investigational agent zoldonrasib elicits objective responses in patients with KRAS G12D-mutated lung cancer

American Association for Cancer Research
Reports and Proceedings

The KRAS G12D inhibitor zoldonrasib elicited responses in patients with KRAS G12D-mutated non-small cell #LungCancer in a phase I clinical trial, according to results presented by Kathryn C. Arbour, MD, at the AACR Annual Meeting 2025.

Meeting: AACR Annual Meeting 2025

Immunotherapy before and after surgery improves outcomes in head and neck cancer

Dana-Farber Cancer Institute
Reports and Proceedings

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.

87
88
89
90
91